Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lenz Therapeutics Inc (LENZ)

Lenz Therapeutics Inc (LENZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 362,651
  • Shares Outstanding, K 31,290
  • Annual Sales, $ 0 K
  • Annual Income, $ -49,770 K
  • EBIT $ -68 M
  • EBITDA $ -72 M
  • 60-Month Beta 0.50
  • Price/Sales 18.49
  • Price/Cash Flow N/A
  • Price/Book 1.94

Options Overview Details

View History
  • Implied Volatility 144.33% (+34.13%)
  • Historical Volatility 76.72%
  • IV Percentile 99%
  • IV Rank 100.00%
  • IV High 144.33% on 02/20/26
  • IV Low 62.29% on 08/14/25
  • Expected Move (DTE 26) 1.49 (12.83%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 243
  • Volume Avg (30-Day) 155
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 6,669
  • Open Int (30-Day) 6,123
  • Expected Range 10.10 to 13.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.91
  • Number of Estimates 6
  • High Estimate -0.70
  • Low Estimate -1.05
  • Prior Year -0.46
  • Growth Rate Est. (year over year) -97.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.50 +0.78%
on 02/20/26
21.80 -46.83%
on 01/22/26
-7.79 (-40.20%)
since 01/20/26
3-Month
11.50 +0.78%
on 02/20/26
32.13 -63.93%
on 11/24/25
-16.13 (-58.19%)
since 11/20/25
52-Week
11.50 +0.78%
on 02/20/26
50.40 -77.00%
on 10/02/25
-13.35 (-53.53%)
since 02/20/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

NEW YORK , Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  LENZ Therapeutics, Inc. ("LENZ" or the "Company") (NASDAQ: LENZ). Such investors are advised...

LENZ : 11.59 (-3.82%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

NEW YORK , Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("LENZ" or the "Company") (NASDAQ: LENZ). Such investors are advised...

LENZ : 11.59 (-3.82%)
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign

Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours The “ Make it VIZZable ” campaign features SJP...

LENZ : 11.59 (-3.82%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

NEW YORK , Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  LENZ Therapeutics, Inc. ("LENZ" or the "Company") (NASDAQ: LENZ). Such investors are advised...

LENZ : 11.59 (-3.82%)
LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates

Launched VIZZ™  (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025 Achieved approximately $1.6 million...

LENZ : 11.59 (-3.82%)
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East

SAN DIEGO and DUBAI, United Arab Emirates, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lunatus Marketing & Consulting FZCO (“Lunatus”) today announced an exclusive...

LENZ : 11.59 (-3.82%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

NEW YORK , Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  LENZ Therapeutics, Inc. ("LENZ" or the "Company") (NASDAQ: LENZ). Such investors are advised...

LENZ : 11.59 (-3.82%)
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia

SAN DIEGO and TAIPEI, Taiwan, Dec. 01, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSW Stock Code: 1795) today announced that Lotus...

LENZ : 11.59 (-3.82%)
LENZ Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine...

LENZ : 11.59 (-3.82%)
LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

VIZZ TM (aceclidine ophthalmic solution) 1.44% received FDA approval for the treatment of presbyopia Commercial product launch initiated in October 2025 with broad product availability in mid-Q4...

LENZ : 11.59 (-3.82%)

Business Summary

Lenz Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision. Its product candidate includes LNZ100 and LNZ101, are preservative-free, single-use, once-daily, aceclidine-based eye drops currently in Phase 3 clinical...

See More

Key Turning Points

3rd Resistance Point 12.71
2nd Resistance Point 12.45
1st Resistance Point 12.02
Last Price 11.59
1st Support Level 11.33
2nd Support Level 11.07
3rd Support Level 10.64

See More

52-Week High 50.40
Fibonacci 61.8% 35.54
Fibonacci 50% 30.95
Fibonacci 38.2% 26.36
Last Price 11.59
52-Week Low 11.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar